Becton Dickinson Gets FDA OK for Molecular Staph Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today announced that it has received US Food and Drug Administration clearance to market its new assay for detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus DNA directly from nasal swabs.

The BD Max StaphSR Assay is for use on the BD Max System, a fully automated molecular diagnostic platform, and can detect mecA dropout mutants and other new strains of MRSA that may not be detected by other assays, said BD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.